Table 3.
Comparison of the NPRL3 and MPG polymorphism frequencies between ischemic stroke subtype patients and controls.
| Genotype | Controls (n = 417) |
LAD (n = 207) |
AOR (95% CI) * | P † | P ‡ | SVD (n = 149) |
AOR (95% CI) * | P † | P ‡ | CE (n = 53) |
AOR (95% CI) * | P † | P ‡ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NPRL3 rs2541618 C>T | |||||||||||||
| CC | 205 (49.2) | 93 (44.9) | 1.000 (reference) | 57 (38.3) | 1.000 (reference) | 22 (41.5) | 1.000 (reference) | ||||||
| CT | 178 (42.7) | 89 (43.0) | 1.040 (0.717–1.509) | 0.835 | 0.870 | 73 (49.0) | 1.375 (0.902–2.097) | 0.138 | 0.185 | 27 (50.9) | 1.402 (0.766–2.568) | 0.274 | 0.737 |
| TT | 34 (8.2) | 25 (12.1) | 1.860 (1.015–3.408) | 0.045 | 0.178 | 19 (12.8) | 2.406 (1.225–4.725) | 0.011 | 0.043 | 4 (7.5) | 1.069 (0.329–3.480) | 0.911 | 0.911 |
| Additive (CC vs. CT vs. TT) | 1.237 (0.946–1.618) | 0.120 | 0.239 | 1.496 (1.102–2.031) | 0.010 | 0.037 | 1.172 (0.747–1.838) | 0.490 | 0.927 | ||||
| Dominant (CC vs. CT+TT) | 1.159 (0.815–1.647) | 0.411 | 0.548 | 1.524 (1.019–2.279) | 0.041 | 0.054 | 1.342 (0.747–2.412) | 0.326 | 0.775 | ||||
| Recessive (CC+CT vs. TT) | 1.832 (1.028–3.262) | 0.040 | 0.160 | 2.059 (1.087–3.899) | 0.027 | 0.106 | 0.893 (0.295–2.701) | 0.841 | 0.841 | ||||
| NPRL3 rs75187722 G>A | |||||||||||||
| GG | 333 (79.9) | 179 (86.5) | 1.000 (reference) | 130 (87.2) | 1.000 (reference) | 43 (81.1) | 1.000 (reference) | ||||||
| GA | 82 (19.7) | 28 (13.5) | 0.622 (0.380–1.017) | 0.058 | 0.207 | 18 (12.1) | 0.474 (0.261–0.860) | 0.014 | 0.056 | 9 (17.0) | 0.835 (0.388–1.797) | 0.644 | 0.737 |
| AA | 2 (0.5) | 0 (0.0) | NA | 0.995 | 0.995 | 1 (0.7) | 1.301 (0.112–15.114) | 0.834 | 0.834 | 1 (1.9) | 2.829 (0.238–33.596) | 0.410 | 0.911 |
| Additive (GG vs. GA vs. AA) | 0.599 (0.370–0.968) | 0.037 | 0.146 | 0.535 (0.306–0.934) | 0.028 | 0.037 | 0.969 (0.491–1.914) | 0.927 | 0.927 | ||||
| Dominant (GG vs. GA+AA) | 0.606 (0.371–0.989) | 0.045 | 0.180 | 0.495 (0.277–0.886) | 0.018 | 0.044 | 0.898 (0.429–1.878) | 0.775 | 0.775 | ||||
| Recessive (GG+GA vs. AA) | NA | 0.996 | 0.996 | 1.468 (0.127–16.980) | 0.759 | 0.759 | 2.690 (0.230–31.473) | 0.430 | 0.841 | ||||
| MPG rs2562162 C>T | |||||||||||||
| CC | 239 (57.3) | 105 (50.7) | 1.000 (reference) | 65 (43.6) | 1.000 (reference) | 28 (52.8) | 1.000 (reference) | ||||||
| CT | 151 (36.2) | 88 (42.5) | 1.359 (0.940–1.965) | 0.103 | 0.207 | 72 (48.3) | 1.569 (1.038–2.372) | 0.033 | 0.066 | 20 (37.7) | 1.156 (0.621–2.152) | 0.647 | 0.737 |
| TT | 27 (6.5) | 14 (6.8) | 1.189 (0.576–2.452) | 0.640 | 0.853 | 12 (8.1) | 1.708 (0.786–3.708) | 0.176 | 0.343 | 5 (9.4) | 1.276 (0.440–3.697) | 0.654 | 0.911 |
| Additive (CC vs. CT vs. TT) | 1.212 (0.916–1.605) | 0.179 | 0.239 | 1.422 (1.040–1.945) | 0.027 | 0.037 | 1.121 (0.718–1.753) | 0.615 | 0.927 | ||||
| Dominant (CC vs. CT+TT) | 1.332 (0.937–1.894) | 0.110 | 0.219 | 1.589 (1.069–2.363) | 0.022 | 0.044 | 1.153 (0.643–2.067) | 0.633 | 0.775 | ||||
| Recessive (CC+CT vs. TT) | 1.052 (0.522–2.121) | 0.886 | 0.996 | 1.412 (0.665–2.996) | 0.369 | 0.492 | 1.179 (0.421–3.300) | 0.754 | 0.841 | ||||
| MPG rs710079 C>T | |||||||||||||
| CC | 290 (69.5) | 151 (72.9) | 1.000 (reference) | 115 (77.2) | 1.000 (reference) | 38 (71.7) | 1.000 (reference) | ||||||
| CT | 118 (28.3) | 55 (26.6) | 0.968 (0.652–1.436) | 0.870 | 0.870 | 33 (22.1) | 0.797 (0.499–1.274) | 0.344 | 0.344 | 14 (26.4) | 0.893 (0.461–1.728) | 0.737 | 0.737 |
| TT | 9 (2.2) | 1 (0.5) | 0.217 (0.026–1.825) | 0.160 | 0.319 | 1 (0.7) | 0.293 (0.035–2.453) | 0.257 | 0.343 | 1 (1.9) | 0.819 (0.098–6.834) | 0.854 | 0.911 |
| Additive (CC vs. CT vs. TT) | 0.858 (0.598–1.231) | 0.406 | 0.406 | 0.738 (0.482–1.129) | 0.161 | 0.161 | 0.894 (0.501–1.594) | 0.704 | 0.927 | ||||
| Dominant (CC vs. CT+TT) | 0.910 (0.616–1.344) | 0.636 | 0.636 | 0.754 (0.476–1.196) | 0.230 | 0.230 | 0.891 (0.468–1.695) | 0.725 | 0.775 | ||||
| Recessive (CC+CT vs. TT) | 0.211 (0.025–1.760) | 0.151 | 0.301 | 0.294 (0.035–2.488) | 0.261 | 0.492 | 0.780 (0.094–6.509) | 0.818 | 0.841 | ||||
AOR, adjusted odds ratio; HWE, Hardy–Weinberg equilibrium; 95% CI, 95% confidence interval; LAD, large-artery disease; SVD, small-vessel disease; CE, cardioembolism; NA, not applicable; NPRL3, nitrogen permease receptor like-3; MPG, N-methylpurine DNA glycosylase. * Adjusted by age, sex, hypertension, diabetes mellitus, hyperlipidemia, and smoking. † P-value calculated by logistic regression analysis; ‡ P-value calculated by false discovery rate test; P-values < 0.05 are shown in bold.